837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro

Podobne zapisy

• A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide
  od: Ge Yang, i wsp.
  Wydane: (2024-09-01)
• Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats
  od: Ami Miller, i wsp.
  Wydane: (2020-01-01)
• Bispecific antibodies: design, therapy, perspectives
  od: Sedykh SE, i wsp.
  Wydane: (2018-01-01)
• Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody
  od: Yan Wang, i wsp.
  Wydane: (2020-01-01)
• The Relevance of Tetravalent Influenza Vaccines. World experience
  od: A. D. M. E. Osterhaus
  Wydane: (2018-09-01)